New computational method exploits the polypharmacology of drugs

March 20, 2014 by Stephanie Dutchen, Harvard Medical School
New computational method exploits the polypharmacology of drugs
A new computational method uses a systems biology approach to distinguish important molecular drug targets from “decoys.” Credit: Kirschner Lab

(Medical Xpress)—If life were simple, a disease could be treated with one drug that hits one molecular target, like striking a piano key. Instead, researchers wrestle with the fact that most drugs hit multiple targets in the body at the same time, like playing a chord. Often, it's not even clear which targets, struck intentionally or inadvertently, lead to which treatment outcomes or side effects.

Researchers have largely avoided studying this phenomenon, called polypharmacology, because it seemed so complex. Now, researchers at Harvard Medical School have used that very complexity to develop a computational method that relates drug targets to outcomes.

"We found a way to turn the tables on a conundrum in pharmacology," said lead co-author Taran Gujral, a research fellow in at HMS. "Polypharmacology has been viewed as a problem, but we decided to embrace it."

"We stepped back from trying to study individual drugs and their targets to instead look at many drugs acting upon many as a system," said lead co-author Leon Peshkin, lecturer on systems biology at HMS.

"We had the right combination of specialists to make it possible: someone with deep knowledge of the biological problem, and someone with the mathematics to devise a solution," said senior author Marc Kirschner, the John Franklin Enders University Professor of Systems Biology and founding chair of the Department of Systems Biology at HMS.

The work provides a way to predict the effects of untested cancer drugs; could guide the design, repurposing and combining of drugs for greater safety and effectiveness; and promises to illuminate hidden details in the molecular circuitry of disease.

The results were published March 19 in Proceedings of the National Academy of Sciences.

A systems approach

The team looked at a class of drugs called , or PKIs. As their name suggests, PKIs block the action of one or more of the 518 protein kinases in the human body. Kinases help regulate many cellular processes, and kinase disruption has been associated with cancer and other diseases.

PKIs have shown promise as a cancer treatment, but they are "notoriously nonspecific" in the kinase targets they strike, Gujral said.

In vitro lab tests may show that a PKI inhibits a particular kinase, but the experimental conditions may not replicate all the interactions that occur in a whole cell, let alone a human body, so secondary targets may remain hidden. Later, clinical trials may show that a PKI achieves the desired treatment result, and if the are tolerable, the time and effort required to systematically determine how many other kinases the drug inhibits along the way may not seem worthwhile.

Instead of attempting the daunting task of testing the effect of every PKI on every kinase one by one, Kirschner's team took a systems biology approach to the problem.

"We examined many PKIs and many kinases together to find out what they jointly uncover about these ," Kirschner said. "We exploited the nonspecificity."

Gujral and Peshkin began by analyzing previously published data about which kinases were being inhibited by which PKIs. These data showed that although PKIs strike many targets, each one has its own unique pattern of targets—a signature musical chord of kinases.

The team devised a way to use the information as a Rosetta stone from which they could mathematically decipher which kinases influence , a hallmark of cancer invasion and metastasis. They identified two classes of kinases that are important for cell migration in certain types of tissue. Then they confirmed their findings in cell cultures.

"We were able to predict the biological response of 150 previously untested PKIs very well," said Peshkin. "Now we can use our method to study thousands of PKIs."

Taking aim

Understanding what specific PKIs do in the body opens many doors.

One of them is the hope of making multidrug therapy a more practical possibility by narrowing down the number of combinations and concentrations to test. The team's results suggest that rather than "tuning" a single PKI to hit a single target—and only that target—precisely, it may be easier to take advantage of the drugs' broad target spread to develop cocktails.

For example, if one PKI hits targets A, B, C and D, and a different PKI hits targets A, E, F and G, then treating a patient with half the dose of both PKIs means target A gets hit just as hard—with less severe side effects, because they're dispersed across more targets.

"The FDA states that you can try combinations of drugs if you have a mechanistic rationale," said Gujral. "Our method provides information to help researchers decide which combinations to try, establishing that rationale."

"There are over 200 PKIs in clinical trials," he added. "Our work suggests we may not need new ones; we may just need to know how to use the current ones most effectively."

The team hopes researchers in academia and industry will start incorporating the new model into their drug discovery and development platforms.

The model also allows researchers to begin to identify kinases for which there currently are no drugs. And it provides an early prediction of how a PKI that hasn't been tested in a whole organism will affect a cellular process.

Finally, the model offers a way to "look under the hood" of how kinases and their associated cellular pathways contribute to health and disease, said Peshkin.

"Being able to see which kinases are affected by a PKI helps us understand whether certain cellular pathways are involved in a disease we're trying to treat," said Kirschner.

"We may be able to investigate whether a pathway is involved not only generally in cell death or cell migration, but also specifically within the heart or the liver or the skin, or in you versus in me," he added. "We can begin to ask questions like what is unique about triple-negative breast cancer."

Explore further: Map of substrate-kinase interactions may lead to more effective cancer drugs

More information: Taranjit Singh Gujral, Leonid Peshkin, and Marc W. Kirschner. "Exploiting polypharmacology for drug target deconvolution," PNAS 2014, published ahead of print March 19, 2014, DOI: 10.1073/pnas.1403080111

Related Stories

Map of substrate-kinase interactions may lead to more effective cancer drugs

March 27, 2012
(Medical Xpress) -- Later-stage cancers thrive by finding detours around roadblocks that cancer drugs put in their path, but a Purdue University biochemist is creating maps that will help drugmakers close more routes and ...

Study finds potential to match tumors with known cancer drugs

February 5, 2013
When it comes to gene sequencing and personalized medicine for cancer, spotting an aberrant kinase is a home run. The proteins are relatively easy to target with drugs and plenty of kinase inhibitors already exist.

Identifying the drivers of breast cancer

June 24, 2013
Information on what causes breast cancer is sorely lacking, making early detection crucial. The sooner breast cancer is found, the greater the chance of treatment and cure.

Recommended for you

Forces from fluid in the developing lung play an essential role in organ development

January 23, 2018
It is a marvel of nature: during gestation, multiple tissue types cooperate in building the elegantly functional structures of organs, from the brain's folds to the heart's multiple chambers. A recent study by Princeton researchers ...

Anemia discovery offers new targets to treat fatigue in millions

January 22, 2018
A new discovery from the University of Virginia School of Medicine has revealed an unknown clockwork mechanism within the body that controls the creation of oxygen-carrying red blood cells. The finding sheds light on iron-restricted ...

More surprises about blood development—and a possible lead for making lymphocytes

January 22, 2018
Hematopoietic stem cells (HSCs) have long been regarded as the granddaddy of all blood cells. After we are born, these multipotent cells give rise to all our cell lineages: lymphoid, myeloid and erythroid cells. Hematologists ...

How metal scaffolds enhance the bone healing process

January 22, 2018
A new study shows how mechanically optimized constructs known as titanium-mesh scaffolds can optimize bone regeneration. The induction of bone regeneration is of importance when treating large bone defects. As demonstrated ...

Researchers illustrate how muscle growth inhibitor is activated, could aid in treating ALS

January 19, 2018
Researchers at the University of Cincinnati (UC) College of Medicine are part of an international team that has identified how the inactive or latent form of GDF8, a signaling protein also known as myostatin responsible for ...

Bioengineered soft microfibers improve T-cell production

January 18, 2018
T cells play a key role in the body's immune response against pathogens. As a new class of therapeutic approaches, T cells are being harnessed to fight cancer, promising more precise, longer-lasting mitigation than traditional, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.